Challenges in managing hepatitis C virus infection in cancer patients

doi:10.3748/wjg.v20.i11.2771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5352)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

409

WORD

202

HTML

2820

Figures (1-1)

177

Tables (1-2)

132

Sum=3740

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

938

Download

674

Sum=1612

Mar 21, 2014 (publication date) through May 5, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Mar 21, 2014; 20(11): 2771-2776
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2771

Open in New Tab Full Size Figure Download Figure

Figure 1 Algorithm for managing chronic hepatitis C virus infection in cancer patients. ¹At least 6 mo after cancer remission before initiating myelosuppressive hepatitis C virus (HCV) treatment with interferon-based therapy. Wait 2 years after hematopoietic stem cell transplant before initiation of interferon-based HCV therapy for patients with normal serum creatinine, normal blood counts, off immunosuppressive therapy > 6 mo, and without evidence of original disease recurrence or graft versus host disease[10]. PegIFN: Pegylated interferon.

Citation: Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol 2014; 20(11): 2771-2776
URL: https://www.wjgnet.com/1007-9327/full/v20/i11/2771.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i11.2771